References
- Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231–43
- Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581–9
- Chang JT, Wong F-H, Liao C-T, Chen I-H, Wang H-M, Cheng A-J. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004; 50: 1261–4
- International Union Against Cancer. TNM classification of malignant tumours5th ed. Wiley-Liss, New York 1997
- Pesarin F. Multivariate permutation tests. John Wiley, ChichesterUK 2001
- Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002; 22: 2377–83
- Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 2004; 45: 180–6
- Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Mariggio A, Salvatore G, et al. Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 2001; 70: 249–54
- Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H, Tanzawa H. Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 2003; 82: 607–11
- Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003; 89: 2244–8
- Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003; 82: 923–8
- Lo Muzio L, Campisi G, Giovannelli L, Ammatuna P, Greco I, Staibano S, et al. HPV DNA and survivin expression in epithelial oral carcinogenesis: a relationship?. Oral Oncol 2004; 40: 736–41
- Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, et al. Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer 2003; 97: 2203–11
- O'Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets 2003; 3: 131–52
- Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004; 199: 69–80
- Grabowski P, Kühnel T, Mühr-Wilkenshoff, Heine B, Stein H, Hüpfner M, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115–9
- Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004; 76: 253–9
- Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004; 216: 147–55
- Zangemeister-Wittke U, Simon HU. An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004; 3: 1121–3
- Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 2005; 114: 509–12
- Sharma H, Sen S, Mathur M, Bahadur S, Singh N. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck 2004; 26: 733–40